Conference Correspondent

Ibrutinib in Patients with Bortezomib-Refractory Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma: 2-Year Results of Safety and Durability of Response

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

The Role of Hepcidin in Multicentric Castleman Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Idiopathic Castleman Disease: Clinical Features and Therapeutic Options

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Restoration of Health with Siltuximab in Multicentric Castleman Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Siltuximab Efficacy in Multicentric Castleman’s Disease Is Independent of Baseline Symptom Burden

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Adding Rituximab to CHOP Improves Clinical Outcomes in Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Long-Term Maintenance with Rituximab in Elderly Patients with Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Antagonism of Immune Effector Function by Ibrutinib or Obinutuzumab versus Rituximab

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Ibrutinib Alone or in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Page 34 of 44

31
32
33
34
35
36
37